HAYA Therapeutics

✈️ Heading to San Diego for the RNA Leaders USA Congress 2024? 🧬 Curious about Novel Dark Genome Therapeutic Targets? Don't miss, HAYA CEO & co-founder, Samir Ounzain talk on “Leveraging Proprietary Technology to Identify Novel lncRNA Therapeutic Targets within the Dark Genome” on Wednesday, September 4, at 11:45 am. For more details visit: https://shorturl.at/foOKy #RNALeaders #lncRNAs #DarkGenome #RNATherapeutics #Biotech

Will you be attending the SAE Media Group 4th annual Oligonucleotide Therapeutics and Delivery conference in London? HAYA’s Director of Computational Biology & Data Science, Marco Mina, will be speaking on "The Dark Genome as the Next Revolution in Drug Discovery”, on Tuesday, September 10, at 14:00h BST. Learn more at: https://shorturl.at/O87xx #SAEMGPharma #RNATherapeutic #lncRNA #RegulatoryGenome #Biotech #OligoTherapeutics

Ever wondered how quickly lncRNAs can shape gene expression? ⏰ 🧬 Today, a groundbreaking study from John Rinn's laboratory and HAYA's Scientific Advisor sheds light on this question. This study reveals that the long non-coding RNA (lncRNA) Firre influences epigenetic and transcriptional states much more rapidly than previously thought —within 15 minutes of induction, and these effects can persist for days. This discovery paves the way for a deeper understanding of the temporal regulatory roles of lncRNAs in epigenetic and transcriptional states. Congratulations to the team! 🚀 Learn more: https://lnkd.in/ePzn5BFw #lncRNA #time #epigenetics #GeneRegulation

This month began with World RNA Day (August 1st), but at HAYA, every day is RNA day! 🌍 🧬 Ribonucleic Acid (RNA) isn't merely a molecular messenger conveying information from our DNA; it's a fundamental building block of life itself. Over the past three decades, scientific discoveries have unveiled various classes of RNA molecules that play pivotal roles in gene expression and regulation, such as long non-coding RNAs (lncRNAs). Today, RNA emerges as a multifaceted player in evolution and cell biology, as well as a game-changer in therapeutics - https://lnkd.in/e23PCc22 At HAYA, we specialize in developing precision therapeutics targeting tissue- and cell state- specific lncRNAs that regulate disease-associated gene pathways. These therapies have the potential to offer greater efficacy and safety, for patients with rare and chronic conditions. Let's continue to celebrate the power of RNA in advancing healthcare and shaping the future of medicine! 🚀 #WorldRNADay #lncRNA #RNATherapeutics #PrecisionMedicine #HealthcareInnovation

98 % des menschlichen Erbguts sind nicht codierend, also nicht für die Herstellung von Proteinen verantwortlich. Dieser Teil wird oft als „dunkle DNA“ bezeichnet; lange Zeit wurde er als „Junk-DNA“ abgetan, doch mittlerweile haben Wissenschaftler die medizinischen Möglichkeiten, die darin stecken, erkannt. Einer von ihnen ist Samir Ounzain – mit seinem Unternehmen HAYA Therapeutics will er mithilfe der „dunklen DNA“ Medikamente für bisher unheilbare Krankheiten entwickeln. Jetzt lesen: https://lnkd.in/dnAPZXsM #Forbes #ForbesDA #HayaTherapeutics

We’re Hiring! 🚀 Join HAYA team and help us to identify and develop breakthrough disease-modifying therapeutics targeting the regulatory genome with the potential for greater efficacy, safety, and accessibility than existing treatments. 🧬 Open Positions: 1. Biomarkers Lead Responsible for developing and implementing biomarker strategies across HAYA's pipeline, with a focus on our RNA-targeted therapeutics. Working with cross-functional teams, you will identify, validate, and implement biomarkers that support our drug development programs from preclinical development through clinical trials and validation. Location: Lausanne, Switzerland🇨🇭, San Diego, CA or Boston, MA 🇺🇸. ➡️ Apply Now:https://lnkd.in/eF-T7B2c 2. IT Manager Responsible to design, deploy, and manage the next generation of HAYA IT platforms, ensuring both data science and global operations needs are met. Location: Lausanne, Switzerland🇨🇭 or San Diego, CA 🇺🇸. ➡️Apply now: https://lnkd.in/eF-T7B2c We are looking for passionate, creative, and driven individuals to join our team. If you’re ready to take on new challenges and be part of a dynamic and collaborative team environment, we’d love to hear from you! 🙌 Please share this post or tag anyone you think would be a great addition to our team. #Hiring #JoinHAYATeam #CareerOpportunities #NowHiring #BiotechJobs #HAYATherapeutics

Today, we welcome Eric Adam as HAYA Chief Operating Officer. Eric Adam brings a wealth of experience in managing strategic alliances, partnerships, and operations within the pharmaceutical and diagnostics industries. His career includes roles at ROCHE, Otsuka Pharmaceuticals, Syrrx and non-profit organizations demonstrating his commitment to global health challenges. We are thrilled to start working with him to help us to streamline operations, focusing on scalable growth and international expansion, while ensuring that HAYA Therapeutics continues to push the boundaries of scientific discovery and development of disease cell states-modifying RNA therapeutics targeting the Regulatory Genome. Welcome to the team Eric! For more information, please read the full release: https://rb.gy/p9v3nk #COO #Leadership #Operations #Welcome #RegulatoryGenome #HAYA

ICYMI: HAYA's been named one of 18 biotechs based in Switzerland to watch by at Labiotech.eu-eu! 🚀 We’re thrilled to be recognized among such innovative peers! Cheers to the Swiss biotech industry and all its groundbreaking companies. #biotech #innovation https://lnkd.in/gnPbAhQ

🗳️ Vote for HAYA Therapeutics in the TOP 100 Swiss Startup Award 2024! The award showcases the 100 most-innovative and promising Swiss startups. Show your support by clicking on 'vote now' in our profile:" https://lnkd.in/gkXHVxwr (you will be taken to your LinkedIn profile in order to finalize the vote) All votes must be submitted by midnight this Sunday, July 21, 2024! #TOP100SSU #SwissStartups Venturelab

Happy 5th Birthday, HAYA! 🥳 Over the past five years, HAYA Therapeutics has undergone a remarkable transformation. What started as a small Swiss biotech focused on lncRNA-targeting therapies for non-obstructive hypertrophic cardiomyopathy has grown into a globally recognized leader in RNA-based precision medicine, pioneering treatments for fibrosis affecting the heart and lungs, and various age-related conditions, including cancer. From developing a groundbreaking platform for reprogramming disease driving cell-states to curating the world's largest lncRNA atlas, we have spent the last five years effectively translating findings from the lab into real-world applications. And now, we are moving them into the clinic, preparing for phase 1 clinical trials in 2025 with our lead candidate Wisper, a cardiac-specific lncRNA that promises to revolutionize the treatment of heart tissue fibrosis. Going into our sixth year, we are primed to fully leverage the power of the regulatory genome in the fight against common, chronic, and underserved rare diseases. None of this would have been possible without the creativity and dedication of our team members in Europe and the US, and the support of our board members and advisors. Join us as we celebrate this milestone anniversary and raise a glass to many more years of inspiration and innovation! 🥂 #5YearAnniversary #lncRNA #HeartHealth